Prescribing patterns for attention deficit hyperactivity disorder medications among children and adolescents in Korea, 2007-2011
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
OBJECTIVES: This study analyzed the prevalence of attention deficit hyperactivity disorder (ADHD) medication use among children and adolescents in Korea between January 1, 2007 and December 31, 2011. METHODS: Using the Korea National Health Insurance claims database, we identified patients between one and 17 years of age who had at least one medical claim for the diagnosis of ADHD (International Classification of Diseases, 10th revision: F90.0). The annual prevalence of ADHD diagnoses was calculated, using national census data from Statistics Korea on the population aged between one and 17 years as the denominator. The prevalence was age-standardized using the 2010 population as the standard population. The number of patients who were treated with methylphenidate and/or atomoxetine and the prevalence of total patients with ADHD that were treated with either drug were also calculated for each year. All analyses were stratified according to gender and age group (1-5 years, 6-12 years, and 13-17 years). RESULTS: The number of patients diagnosed with ADHD increased from 72,704 persons (0.71%) in 2007 to 85,468 persons (0.93%) in 2011. The annual age-standardized prevalence of ADHD diagnoses increased from 0.67% in 2007 to 0.94% in 2011. The prevalence of methylphenidate use among children and adolescents with ADHD decreased from 73.91% in 2007 to 70.33% in 2011, whereas that of atomoxetine use increased from 5.77% in 2009 to 13.09% in 2011. CONCLUSIONS: While methylphenidate remains the most commonly prescribed ADHD drug, the use of atomoxetine has increased.
Abstract
OBJECTIVES: This study analyzed the prevalence of attention deficit hyperactivity disorder (ADHD) medication use among children and adolescents in Korea between January 1, 2007 and December 31, 2011. METHODS: Using the Korea National Health Insurance claims database, we identified patients between one and 17 years of age who had at least one medical claim for the diagnosis of ADHD (International Classification of Diseases, 10th revision: F90.0). The annual prevalence of ADHD diagnoses was calculated, using national census data from Statistics Korea on the population aged between one and 17 years as the denominator. The prevalence was age-standardized using the 2010 population as the standard population. The number of patients who were treated with methylphenidate and/or atomoxetine and the prevalence of total patients with ADHD that were treated with either drug were also calculated for each year. All analyses were stratified according to gender and age group (1-5 years, 6-12 years, and 13-17 years). RESULTS: The number of patients diagnosed with ADHD increased from 72,704 persons (0.71%) in 2007 to 85,468 persons (0.93%) in 2011. The annual age-standardized prevalence of ADHD diagnoses increased from 0.67% in 2007 to 0.94% in 2011. The prevalence of methylphenidate use among children and adolescents with ADHD decreased from 73.91% in 2007 to 70.33% in 2011, whereas that of atomoxetine use increased from 5.77% in 2009 to 13.09% in 2011. CONCLUSIONS: While methylphenidate remains the most commonly prescribed ADHD drug, the use of atomoxetine has increased.
참고문헌 (13)
- Visser SN, "Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit", hyperactivity disorder: United States, 2003-2011, 2014, pp.53, 34~46.e2
- Chai G, "Trends of outpatient prescription drug utilization in US children, 2002-2010", Pediatrics, 130, pp.23~31 (2012)
- McCarthy S, "The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care", BMC Pediatr, 12, pp.78~ (2012)
- Kenneth K. C. Man, "ADHD Drug Prescribing Trend Is Increasing Among Children and Adolescents in Hong Kong", Journal of Attention Disorders, 21(14), pp.1161~1168 (2014), SAGE Publications[DOI]
- Bédard AC, "Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit", hyperactivity disorder, 2015, pp.56, 40~48
- Du DT, "Atomoxetine use during a period of FDA actions", Med Care, 50, pp.987~992 (2012)
- Hong M, "Nationwide rate of attention-deficit hyperactivity disorder diagnosis and pharmacotherapy in Korea in 2008-2011", Asia Pac Psychiatry, 6, pp.379~385 (2014)
- Brault MC, "Prevalence of prescribed attention-deficit hyperactivity disorder medications and diagnosis among Canadian preschoolers and school-age children : 1994-2007", Can J Psychiatry, 57, pp.93~101 (2012)
- 양수진, "주의력 결핍 과잉 행동 장애의 유병률과 관련 인자 : 서울시 학교 정신보건 사업", 신경정신의학, 45(1), pp.69~76 (2006), 대한신경정신의학회
- Getahun D, "Recent trends in childhood attention-deficit", hyperactivity disorder, 2013, pp.167, 282~288
- Shin JY, "Regulatory action and moderate decrease in methylphenidate use among ADHD diagnosed patients aged five and under in Korea", Regul Toxicol Pharmacol, 72, pp.244~248 (2015)
- Pottegård A, "The use of medication against attention deficit", hyperactivity disorder in Denmark: a drug use study from a patient perspective, 2013, pp.69, 589~598
- "Drug reimbursement notice" (2016)[URL]